Vibrio Vulnificus Infection

Back

Background

Vibrio vulnificus is a gram-negative bacillus that only affects humans and other primates. It is in the same family as bacteria that cause cholera. The first documented case of disease caused by the organism was in 1979.

V vulnificus is usually found in warm, shallow, coastal salt water in temperate climates throughout most of the world. It can be found in the Gulf of Mexico, along most of the East Coast of the United States, and along all of the West Coast of the United States. V vulnificus can be found in water; sediment; plankton; and shellfish, such as oysters, clams, and crabs. This organism can survive in seawater and can produce wound infections, a potentially serious problem among Asian tsunami survivors,[1] and potentially fatal necrotizing fasciitis in them and in individuals with liver cirrhosis.[2] This halophilic bacterium can also cause serious gastroenteritis after eating raw seafood.[3] Genome sequencing has been performed.[4]

See image below, as well as the article Vibrio Infections.



View Image

Vibrio infections. Early bullous lesions appear over the dorsum of the foot of a patient with cirrhosis.

Pathophysiology

V vulnificus infects the body in 2 ways, either by exposure to contaminated seafood, such as raw oysters, or through an open wound exposed to contaminated seawater. Among healthy individuals, within 16 hours of ingestion, they experience vomiting, diarrhea, and abdominal pain. Many patients develop distinctive bullous skin lesions. In patients who are immunocompromised, particularly those with chronic liver disease (especially cirrhosis), immunosuppression, end-stage renal disease, and hematopoietic disorders, V vulnificus can cause life-threatening septic shock and blistering skin lesions. Those who are immunocompromised are at a much greater risk for contracting V vulnificus and dying from overwhelming sepsis.

Because the incidence of disease is relatively low, not all strains of V vulnificus may be equally virulent. Recent data are consistent with the existence of 2 genotypes of V vulnificus, with the C-type being a strong indicator of potential virulence.[5] The biotype 3 group of the human pathogen V vulnificus may have emerged in Israel due to genome hybridization of 2 bacterial populations. This new clonal subgroup emphasizes that the fish aquaculture environment, and possibly manmade ecological niches as a whole, may be a source of new pathogenic strains.[6]

Etiology

See Pathophysiology.

It is seen in a variety of seafood. V vulnificus can grow rapidly in shellfish owing to the ambient air conditions occurring with intertidal exposure.[7] A study of Vibrio species isolated from retail shrimp in Hanoi found 201 of 202 samples were positive, with most having Vibrio parahaemolyticus (96.5%) and V vulnificus documented much less often, specifically in only 1.5%.[8] Sanitary working conditions and well-cooked shrimp should be encouraged.

Epidemiology

United States

V vulnificus infections are rare but underreported. Most cases are found in the Gulf Coast states, and they are most common during warm weather months. V vulnificus has been difficult to culture from North Carolina oyster samples since 2007. It may be that oysters were colonized with a more salt-tolerant bacterium during the drought, displacing V vulnificus, and may be preventing recolonization.[9] Evaluation of the graveyard skeletons of two American Civil War soldiers revealed they may have died as a result of V vulnificus septicemia.[10]

International

The frequency of V vulnificus infection, which is rare in Japan, was evaluated in 2008. Its prevalence varied in different districts.[11] A 2017 study from India found that 10 (38.5%) of 26 clam (Meretrix meretrix) samples obtained from the markets in the attractive tourist destination of Mangalore harbored V vulnificus.[12] Marine aquaculture has rendered V vulnificus infections relatively common all over the world.[13]

Race

All races are affected equally.

Sex

Males and females are affected equally.

Age

All ages are affected equally.

Prognosis

Vibrio vulnificus infection is an acute illness that is quickly resolved with antibiotics and does not have any long-term consequences. The prognosis is often excellent with proper treatment. However, it produces more than 95% of seafood-related deaths in the United States and has the highest fatality rate of any food-borne pathogen.[14]

Most V vulnificus infections are acute but have no long-term consequences; however, in patients who develop septic shock from infection with V vulnificus, the mortality rate is 50%. A 2017 case report describes a man becoming infected with V vulnificus after swimming in the Gulf of Mexico 5 days after the completion of a leg tattoo.[15] The patient died from septic shock; his chronic liver disease was cited as a possible contributing factor.

In rare instances, skin infection can result in necrotizing fasciitis. V vulnificus necrotizing skin and soft-tissue infections may result in multiple organ failure and death. A prediction model to estimate the case-fatality rate has been proposed.[16]

Retrospective analysis of 30 patients with necrotizing fasciitis and sepsis caused by Vibrio species and initially treated with surgical debridement or immediate limb amputation showed 11 (37%) died within several days of admission.[17] A higher mortality rate was noted with the Vibrio cholerae non-O1 group (57%) compared with the V vulnificus group (30%). Other bad prognostic signs included a systolic blood pressure of less than or equal to 90 mm Hg, decreased platelet counts, and leukopenia. The combination of hepatic dysfunction and diabetes mellitus was also associated with a poor outcome.

Predictive factors for mortality in primary septicemia or wound infections caused by V vulnificus have been accessed using a variety of parameters. Multivariate analysis has revealed that the presence of hemorrhagic bullae/necrotizing fasciitis, primary septicemia, a greater severity of illness, absence of leukocytosis, and hypoalbuminemia were the significant risk factors for mortality in V vulnificus skin and soft tissue infections.[18]

The presence of hemorrhagic bullous skin lesions, necrotizing fasciitis, primary septicemia, a greater severity-of-illness, absence of leukocytosis, and hypoalbuminemia were found to be the significant risk factors for mortality in patients with V vulnificus infection.[18]

Patient Education

Counsel patients who are immunocompromised to prevent exposure to V vulnificus. The high mortality associated with this septicemia suggests susceptible individuals should be forewarned by signs displayed in restaurants; physicians should educate patients with chronic liver disease about the risk of raw oyster consumption. Additionally, harvesting methods that reduce contamination by V vulnificus should be used.[19]

History

V vulnificus infection should be suspected in patients who give a history of ingestion of raw seafood or wound infection after exposure to seawater. Patients with V vulnificus infection report abrupt GI symptoms, such as vomiting, diarrhea, or abdominal pain, and may present with fever, chills, or shock. V vulnificus is normally found in warm estuarial and marine environments, lodging in filter feeders such as oysters. It occurs mainly in patients with chronic liver disease after the consumption of raw oysters. Partridge et al reported a case that was likely contracted from a thermal pool in Turkey, with no history of seawater or shellfish exposure.[20]

V vulnificus septicemia is the most common cause of death from seafood consumption in the United States.[19] V vulnificus septicemia may first become evident in the skin as purpura fulminans, which can take a catastrophic course without immediate and intensive empirical antibiotic treatment.[21]

V vulnificus infection is a rare cause of necrotizing fasciitis, which can be fatal.[22, 23] Necrotizing fasciitis caused by V vulnificus progresses more rapidly with clinical characteristics more fulminant than either methicillin-resistant Staphylococcus aureus or methicillin-sensitive S aureus infection.[24]  The same may be true for V vulnificus as compared with Klebsiella pneumoniae–induced necrotizing fasciitis, being 2.5 days versus 5.5 days.[25]

Physical Examination

Most patients infected with V vulnificus have bullous skin lesions, which are found on the trunk and the lower extremities (see the image below). Infection of the hand has been reported.[26] These hemorrhagic bullae can progress to necrotic ulcerations, which require surgical debridement. Edema can be present.



View Image

Vibrio infections. Early bullous lesions appear over the dorsum of the foot of a patient with cirrhosis.

A rapid onset of cellulitis may represent infection with V vulnificus, especially if the patient had contact with seawater or raw seafood. Patients can progress to necrotizing fasciitis.[27]

Complications

Patients who are immunocompromised are at risk of septic shock from the infection, which can be fatal. Otherwise, no complications from V vulnificus infection occur.

Laboratory Studies

Routine stool, wound, and blood cultures aid in the diagnosis of V vulnificus infection. A polymerase chain reaction assay is a super detection method for V vulnificus.[28]

Imaging Studies

No imaging studies are necessary to help diagnose or treat V vulnificus infection.

Medical Care

Antibiotics are necessary to eradicate the infection (see Medication). In case of wound infection, aggressive debridement is necessary to remove necrotic tissue. If the patient is in shock, perform necessary interventions to resuscitate the patient. V vulnificus as the etiologic agent of necrotizing fasciitis requires emergency approaches to treat potential septic shock and multiple organ failure,[29] particularly in those with preexisting medical complications, including hypotension, lactic acidosis, coagulation disorders, and thrombocytopenia.[30]

Available guidelines that may be helpful include the Practice guidelines for the diagnosis and management of skin and soft-tissue infections from the Infectious Diseases Society of America and the Diagnosis and management of foodborne illnesses: a primer for physicians and other health care professionals from the American Medical Association, American Nurses Association, American Nurses Foundation, Centers for Disease Control and Prevention, Center for Food Safety and Applied Nutrition, US Food and Drug Administration, Food Safety and Inspection Service, and US Department of Agriculture.[31, 32]

Consultations

Because many patients with V vulnificus infection experience overwhelming sepsis, consultation with an infectious disease specialist is warranted. Consider consultation with an infectious disease specialist if the diagnosis is unclear or if the patient has atypical symptoms or does not respond to antibiotic treatment.

Activity

No restrictions are necessary.

Prevention

To prevent infection from V vulnificus, persons should avoid exposure to raw shellfish or thoroughly cook the shellfish. Persons should avoid cross-contamination of cooked shellfish with uncooked shellfish and eat shellfish promptly after cooking. Shellfish is best served hot.[33]

Identifying oysters that are affected by V vulnificus is difficult because the appearance, taste, color, and odor of the oysters are not affected. Through improved reporting of affected oysters, oyster beds that are affected can be identified and closed.[34]

Persons should avoid exposure of open wounds or broken skin to raw shellfish or infected waters. Patients who are immunocompromised should be especially careful to follow these guidelines because they are more susceptible to infection and complications.

Therapeutic vaccination against V vulnificus infection by active and passive immunization with the C-terminal region of the RtxA1/MARTXVv protein has been suggested by studies in mice.[35]

Medication Summary

The goals of therapy are to eradicate the infection, to reduce morbidity, and to prevent complications. A high index of suspicion is important, as doxycycline, the antibiotic of choice, is not usually a part of the empiric therapy for septicemia. Tigecycline may be a good choice for treating invasive V vulnificus infections.[36]

If necrotizing fasciitis is suspected, early fasciotomy and culture-directed antimicrobial therapy should be performed. These patients may develop hypotensive shock, leukopenia, severe hypoalbuminemia, and underlying chronic illness, especially a combination of hepatic dysfunction and diabetes mellitus.

Doxycycline (Doryx, Vibramycin, Bio-Tab)

Clinical Context:  Doxycycline is a synthetic antibiotic derived from tetracycline. It inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. Doxycycline is effective against a large number of pathogens.

Class Summary

Antibiotics are necessary to eradicate V vulnificus infection. Effective antibiotics may include tetracycline, third-generation cephalosporins, and imipenem.

What is Vibrio vulnificus infection?What is the pathophysiology of Vibrio vulnificus infection?What causes Vibrio vulnificus infection?What is the prevalence of Vibrio vulnificus infection in the US?What is the global prevalence of Vibrio vulnificus infection?What is the racial predilection of Vibrio vulnificus infection?What is the sexual predilection of Vibrio vulnificus infection?How does the prevalence of Vibrio vulnificus infection vary by age?What is the prognosis of Vibrio vulnificus infection?What is included in patient education about Vibrio vulnificus infection?Which clinical history findings are characteristic of Vibrio vulnificus infection?Which physical findings are characteristic of Vibrio vulnificus infection?What are the possible complications of Vibrio vulnificus infection?Which lab tests are performed in the diagnosis of Vibrio vulnificus infection?What is the role of imaging studies in the diagnosis of Vibrio vulnificus infection?How is Vibrio vulnificus infection treated?Which specialist consultations are beneficial to patients with Vibrio vulnificus infection?Which activity modifications are used in the treatment of Vibrio vulnificus infection?How is Vibrio vulnificus infection prevented?What is the role of medications in the treatment of Vibrio vulnificus infection?Which medications in the drug class Antibiotics are used in the treatment of Vibrio Vulnificus Infection?

Author

Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Pathology, Professor of Pediatrics, Professor of Medicine, Rutgers New Jersey Medical School

Disclosure: Nothing to disclose.

Coauthor(s)

Cris Jagar, MD, Staff Physician, Department of Psychiatry, Trinitas Regional Medical Center

Disclosure: Nothing to disclose.

Specialty Editors

David F Butler, MD, Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD, Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Disclosure: Received honoraria from UpToDate for author/editor; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for i inherited these trust accounts; for: Allergen; Celgene; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble; Amgen.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Craig A Elmets, MD, Professor and Chair, Department of Dermatology, Director, Chemoprevention Program Director, Comprehensive Cancer Center, UAB Skin Diseases Research Center, University of Alabama at Birmingham School of Medicine

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: University of Alabama at Birmingham; University of Alabama Health Services Foundation<br/>Serve(d) as a speaker or a member of a speakers bureau for: Ferndale Laboratories<br/>Received research grant from: NIH, Veterans Administration, California Grape Assn<br/>Received consulting fee from Astellas for review panel membership; Received salary from Massachusetts Medical Society for employment; Received salary from UpToDate for employment. for: Astellas.

References

  1. Lim PL. Wound infections in tsunami survivors: a commentary. Ann Acad Med Singapore. 2005 Oct. 34(9):582-5. [View Abstract]
  2. Park SY, Yu SN, Lee EJ, Kim T, Jeon MH, Choo EJ, et al. Monomicrobial gram-negative necrotizing fasciitis: An uncommon but fatal syndrome. Diagn Microbiol Infect Dis. 2019 Jan 4. [View Abstract]
  3. Phillips KE, Satchell KJ. Vibrio vulnificus: From Oyster Colonist to Human Pathogen. PLoS Pathog. 2017 Jan. 13 (1):e1006053. [View Abstract]
  4. Tiba-Casas MR, Lemes-Marques EG, Almeida EA, Soares FB, Camargo CH. Draft Genome Sequence of a Pathogenic Vibrio vulnificus Strain Isolated in Brazil. Genome Announc. 2018 Feb 15. 6 (7):[View Abstract]
  5. Rosche TM, Yano Y, Oliver JD. A rapid and simple PCR analysis indicates there are two subgroups of Vibrio vulnificus which correlate with clinical or environmental isolation. Microbiol Immunol. 2005. 49(4):381-9. [View Abstract]
  6. Broza YY, Raz N, Lerner L, Danin-Poleg Y, Kashi Y. Genetic diversity of the human pathogen Vibrio vulnificus: a new phylogroup. Int J Food Microbiol. 2012 Feb 15. 153(3):436-43. [View Abstract]
  7. Jones JL, Kinsey TP, Johnson LW, Porso R, Friedman B, Curtis M, et al. Effects of Intertidal Harvest Practices on Vibrio parahaemolyticus and Vibrio vulnificus Levels in Oysters. Appl Environ Microbiol. 2016 May 20. [View Abstract]
  8. Tra VT, Meng L, Pichpol D, Pham NH, Baumann M, Alter T, et al. Prevalence and antimicrobial resistance of Vibrio spp. in retail shrimps in Vietnam. Berl Munch Tierarztl Wochenschr. 2016 Jan-Feb. 129 (1-2):48-51. [View Abstract]
  9. Froelich BA, Williams TC, Noble RT, Oliver JD. Apparent Loss of Vibrio vulnificus from North Carolina Oysters Coincides with a Drought-Induced Increase in Salinity. Appl Environ Microbiol. 2012 Jun. 78(11):3885-9. [View Abstract]
  10. Barbieri R, Aboudharam G, Raoult D, Drancourt M. Vibrio vulnificus casualties during the American Civil War. Lancet Infect Dis. 2020 Feb. 20 (2):170-171. [View Abstract]
  11. Inoue Y, Ono T, Matsui T, Miyasaka J, Kinoshita Y, Ihn H. Epidemiological survey of Vibrio vulnificus infection in Japan between 1999 and 2003. J Dermatol. 2008 Mar. 35(3):129-39. [View Abstract]
  12. Sangeetha MS, Shekar M, Venugopal MN. Occurrence of clinical genotype Vibrio vulnificus in clam samples in Mangalore, Southwest coast of India. J Food Sci Technol. 2017 Mar. 54 (3):786-791. [View Abstract]
  13. Li G, Wang MY. The role of Vibrio vulnificus virulence factors and regulators in its infection-induced sepsis. Folia Microbiol (Praha). 2020 Apr. 65 (2):265-274. [View Abstract]
  14. Baker-Austin C, Oliver JD. Vibrio vulnificus: new insights into a deadly opportunistic pathogen. Environ Microbiol. 2018 Feb. 20 (2):423-430. [View Abstract]
  15. Hendren N, Sukumar S, Glazer CS. Vibrio vulnificus septic shock due to a contaminated tattoo. BMJ Case Rep. 2017 May 27. 2017:[View Abstract]
  16. Huang KC, Tsai YH, Huang KC, Lee MS. Model for End-Stage Liver Disease (MELD) Score as a Predictor and Monitor of Mortality in Patients with Vibrio vulnificus Necrotizing Skin and Soft Tissue Infections. PLoS Negl Trop Dis. 2015 Apr. 9 (4):e0003720. [View Abstract]
  17. Tsai YH, Huang TJ, Hsu RW, et al. Necrotizing soft-tissue infections and primary sepsis caused by Vibrio vulnificus and Vibrio cholerae non-O1. J Trauma. 2009 Mar. 66(3):899-905. [View Abstract]
  18. Kuo Chou TN, Chao WN, Yang C, Wong RH, Ueng KC, Chen SC. Predictors of Mortality in Skin and Soft-tissue Infections Caused by Vibrio vulnificus. World J Surg. 2010 Feb 12. [View Abstract]
  19. Haq SM, Dayal HH. Chronic liver disease and consumption of raw oysters: a potentially lethal combination--a review of Vibrio vulnificus septicemia. Am J Gastroenterol. 2005 May. 100(5):1195-9. [View Abstract]
  20. Partridge DG, Townsend R, Larkin S, Parsons HK. Vibrio vulnificus: an unusual mode of acquisition and novel use of rapid susceptibility testing. J Clin Pathol. 2009 Apr. 62(4):370-2. [View Abstract]
  21. Choi HJ, Lee DK, Lee MW, Choi JH, Moon KC, Koh JK. Vibrio vulnificus septicemia presenting as purpura fulminans. J Dermatol. 2005 Jan. 32(1):48-51. [View Abstract]
  22. Tajiri T, Tate G, Akita H, et al. Autopsy cases of fulminant-type bacterial infection with necrotizing fasciitis: group A (beta) hemolytic Streptococcus pyogenes versus Vibrio vulnificus infection. Pathol Int. 2008 Mar. 58(3):196-202. [View Abstract]
  23. Kitamura C, Yamauchi Y, Yamaguchi T, Aida Y, Ito K, Ishizawa Y, et al. Successful Treatment of a Case of Necrotizing Fasciitis due to Vibrio vulnificus in a Cold Climate in Japan. Intern Med. 2016. 55 (8):1007-10. [View Abstract]
  24. Tsai YH, Wen-Wei Hsu R, Huang KC, Huang TJ. Comparison of necrotizing fasciitis and sepsis caused by Vibrio vulnificus and Staphylococcus aureus. J Bone Joint Surg Am. 2011 Feb. 93(3):274-84. [View Abstract]
  25. de Klerk A. Should a patient have access to his medical records. Med Law. 1989. 8 (5):475-83. [View Abstract]
  26. Inoue H. Vibrio vulnificus infection of the hand. J Orthop Sci. 2006 Jan. 11(1):85-7. [View Abstract]
  27. Tsai YH, Hsu RW, Huang TJ, et al. Necrotizing soft-tissue infections and sepsis caused by Vibrio vulnificus compared with those caused by Aeromonas species. J Bone Joint Surg Am. 2007 Mar. 89(3):631-6. [View Abstract]
  28. Tsai YH, Chen PH, Yu PA, Chen CL, Kuo LT, Huang KC. A multiplex PCR assay for detection of Vibrio vulnificus, Aeromonas hydrophila, methicillin-resistant Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus agalactiae from the isolates of patients with necrotizing fasciitis. Int J Infect Dis. 2019 Apr. 81:73-80. [View Abstract]
  29. Lee YC, Hor LI, Chiu HY, Lee JW, Shieh SJ. Prognostic factor of mortality and its clinical implications in patients with necrotizing fasciitis caused by Vibrio vulnificus. Eur J Clin Microbiol Infect Dis. 2014 Jun. 33(6):1011-8. [View Abstract]
  30. Hong G, Wu B, Lu C, Li M, Zhao G, Lu Z. Emergency treatment of 16 patients with necrotizing fasciitis caused by Vibrio vulnificus infection complicated with septic shock. Chin Med J (Engl). 2014 May. 127(10):1984-6. [View Abstract]
  31. [Guideline] American Medical Association; American Nurses Association-American Nurses Foundation; Centers for Disease Control and Prevention; et al. Diagnosis and management of foodborne illnesses: a primer for physicians and other health care professionals. MMWR Recomm Rep. 2004 Apr 16. 53:1-33. [View Abstract]
  32. [Guideline] Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jul 15. 59(2):e10-52. [View Abstract]
  33. Prutkin JM, Haq R. A dish best served hot. Am J Med. 2006 Apr. 119(4):307-9. [View Abstract]
  34. Mouzin E, Mascola L, Tormey MP, Dassey DE. Prevention of Vibrio vulnificus infections. Assessment of regulatory educational strategies. JAMA. 1997 Aug 20. 278(7):576-8. [View Abstract]
  35. Lee TH, Kim MH, Lee CS, Lee JH, Rhee JH, Chung KM. Protection against Vibrio vulnificus infection by active and passive immunization with the C-terminal region of the RtxA1/MARTXVv protein. Vaccine. 2014 Jan 3. 32(2):271-6. [View Abstract]
  36. Tang HJ, Chen CC, Lai CC, Zhang CC, Weng TC, Chiu YH, et al. In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus. J Microbiol Immunol Infect. 2018 Feb. 51 (1):76-81. [View Abstract]

Vibrio infections. Early bullous lesions appear over the dorsum of the foot of a patient with cirrhosis.

Vibrio infections. Early bullous lesions appear over the dorsum of the foot of a patient with cirrhosis.

Vibrio infections. Early bullous lesions appear over the dorsum of the foot of a patient with cirrhosis.